1 terminated, 1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Eric Bernicker, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma ADV/HSV-tk, Valacyclovir, SBRT - Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung | Phase 2 | Terminated | Eric Bernicker, MD | 11 | 2017-02-15 | 2023-09-21 |
| Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies Brentuximab Vedotin, Alsertib - CD30-positive Lymphoma, CD30-positive Solid Tumor | Phase 1 | Withdrawn | Eric Bernicker, MD | 2015-12-01 | 2018-07-27 |
Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Recurrence (1) · Uveal Melanoma (1)
Brentuximab Vedotin (1) · MLN 8237 (1) · Nivolumab (1) · Valacyclovir (1)
United States (2)